Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck KGaA Passes EXCiPACT Audit for Certification as Provider of Pharmaceutical Excipients

Published: Friday, August 02, 2013
Last Updated: Friday, August 02, 2013
Bookmark and Share
Ensures current GMP and GDP requirements applied to pharmaceutical excipients through a recognized auditing and certification process.

Merck Millipore has announced that Merck KGaA is one of the first companies to undergo and successfully complete a comprehensive EXCiPACT™ audit.

The audit ensures current GMP and GDP requirements are applied to pharmaceutical excipients through a recognized auditing and certification process covering quality management systems, manufacturing, testing and release, and storage and distribution.

This certification reduces the time and money pharmaceutical companies must invest to comply with GMP regulations and will help secure the overall excipient supply chain.

"Thousands of excipients are present in medicines and the quality of these materials is critical to ensure patient safety," said Burghard Freiberg, Senior Vice President, Pharmaceutical Chemicals Solutions, Merck Millipore.

Freiberg continued, "This EXCiPACT audit will assure our customers they are incorporating only the highest quality excipients into their formulations and we have minimized risk in their supply chains. We encourage all manufacturers of excipients to undergo the same audit."

Launched in 2012, EXCiPACT is a voluntary, international certification scheme to provide independent, third-party certification of manufacturers, suppliers and distributors of pharmaceutical excipients.

Audits conducted on behalf of the EXCiPACT association will ensure patient safety through supplier quality, while minimizing the overall costs for assessing the excipient supply chain.

EXCiPACT is a project under the International Pharmaceutical Excipients Council (IPEC) Federation, a global organization that promotes quality in pharmaceutical excipients.

"Collaborating with the EXCiPACT association to execute this audit was an important step for our company and our customers," said Matthias Bucerius, Director of Pharmaceutical Raw Materials, Merck Millipore.

Bucerius continued, "Following this positive assessment, we will undergo recertification audits every three years, with annual surveillance audits to ensure the continued safety and quality of our excipients."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Announces Incoming CEO and President
Udit Batra, Ph.D. will be responsible for the organization’s strategic direction to drive growth and product innovation as well as oversight of the worldwide operations.
Tuesday, April 15, 2014
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!